Lobbying Law Should Not Deter Researchers From Speaking Out On Behalf Of Science

From Speaking Out On Behalf Of Science At the end of 1995, the United States Congress enacted a new lobbying law, replacing a hodgepodge of vague disclosure requirements adopted over the previous 40 years. The intent of the new law is to provide the public with an accurate listing of the people and organizations involved in lobbying and a general accounting of funds expended on such activities. As research institutions consider their responsibilities under the new law, faculty and administrato

Written byApril Burk
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

From Speaking Out On Behalf Of Science April Burke At the end of 1995, the United States Congress enacted a new lobbying law, replacing a hodgepodge of vague disclosure requirements adopted over the previous 40 years. The intent of the new law is to provide the public with an accurate listing of the people and organizations involved in lobbying and a general accounting of funds expended on such activities. As research institutions consider their responsibilities under the new law, faculty and administrators may become concerned that their interactions with Congress and executive branch agencies "brand" them as lobbyists.

But this is a time when scientists need to be science advocates, resisting the inference that the Lobbying Disclosure Act is a deterrent to communicating with policy-makers about the federal science investment. Although broader than the old law, the new legislation is not intended to "catch" people who occasionally make their views known about ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies